Meeting
2020 ASCO Virtual Scientific Program
Use of plasma androgen receptor (AR) testing to optimize docetaxel chemotherapy in castration-resistant prostate cancer (CRPC): A multicenter biomarker study.
Authors
Vincenza Conteduca
IRCCS-IRST (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Meldola, Italy
Vincenza Conteduca , Elena Castro , Daniel Wetterskog , Emanuela Scarpi , Nuria Romero-Laorden , Giorgia Gurioli , Anuradha Jayaram , Cristian Lolli , Giuseppe Schepisi , Anna Wingate , Chiara Casadei , Rebeca Lozano , Nicole Brighi , Isabel Aragon , Mercedes Marín-Aguilera , Enrique González-Billalabeitia , Begona Mellado , David Olmos , Gerhardt Attard , Ugo De Giorgi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5546)
DOI
10.1200/JCO.2020.38.15_suppl.5546
Abstract #
5546
Poster Bd #
127
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Dana E. Rathkopf
Poster
2023 ASCO Genitourinary Cancers Symposium
CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.
First Author: Simon J. Crabb
Poster
2023 ASCO Genitourinary Cancers Symposium
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
First Author: Alice Bernard-Tessier
Poster
2023 ASCO Genitourinary Cancers Symposium
Utilization of metastatic hormone sensitive prostate cancer (mHSPC) treatment in a community oncology practice setting.
First Author: Terri Conner